Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer Patients: A Population-based Study.
AUTHORS
Tsai
HT ,
Pfeiffer
RM ,
Philips
GK ,
Barac
A ,
Fu
AZ ,
Penson
DF ,
Zhou
Y ,
Potosky
AL ,
. The Journal of urology. 2016 12 16; ().
- NIHMSID: 0376374
ABSTRACT
Randomized trials have reported that intermittent androgen deprivation therapy (IADT) for patients with advanced prostate cancer (PCa) may improve sexual and physical functioning compared to continuous ADT (CADT) without compromising survival. It is unknown whether IADT alters the risk of serious toxicities associated with CADT.
Randomized trials have reported that intermittent androgen deprivation therapy (IADT) for patients with advanced prostate cancer (PCa) may improve sexual and physical functioning compared to continuous ADT (CADT) without compromising survival. It is unknown whether IADT alters the risk of serious toxicities associated with CADT.
Tags: Faculty Publications 2016